ERR2208914
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- TNFA_SIGNALING_VIA_NFKB+0.500
- ALLOGRAFT_REJECTION+0.400
- COMPLEMENT+0.400
- INFLAMMATORY_RESPONSE+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- CHOLESTEROL_HOMEOSTASIS+0.300
- COAGULATION+0.300
- HYPOXIA+0.300
Top 10 suppressed
- UV_RESPONSE_DN-0.300
- HEDGEHOG_SIGNALING-0.200
- BILE_ACID_METABOLISM-0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.100
- NOTCH_SIGNALING-0.100
- PROTEIN_SECRETION-0.100
- WNT_BETA_CATENIN_SIGNALING-0.100
- ADIPOGENESIS+0.000
- ANDROGEN_RESPONSE+0.000
- APICAL_JUNCTION+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1072 | — | — | 0.870 |
| 2 | SRR975600 | — | — | 0.867 |
| 3 | GSM6454748 | — | C | 0.858 |
| 4 | SRR8518246 | — | C | 0.855 |
| 5 | SRR821019 | GTEX | — | 0.847 |
| 6 | TCGA-BT-A42F-01A-11R-A23W-07 | — | — | 0.846 |
| 7 | BS_GJNCYABP | ATRT | — | 0.844 |
| 8 | TCGA-UY-A78P-01A-12R-A36F-07 | — | — | 0.843 |
| 9 | BS_996ZS2A4 | ATRT | — | 0.842 |
| 10 | TCGA-60-2698-01A-01R-0851-07 | — | cohortSQ1 | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.500 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |